PDS Biotechnology Corporation (PDSB) Stock: A Biotech Stock That’s Headed Down


PDS Biotechnology Corporation (PDSB) is trending down in the market today. The stock, focused in the biotechnology space, is presently trading at $6.02 after tumbling -8.09% so far in today’s session. In terms of biotechnology stocks, there are several factors that have the ability to generate price movement in the market. One of the most common is news. Here are the recent stories centered around PDSB:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jul-03-19 08:30AM PDS Biotechnology Corporation Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jun-19-19 08:30AM PDS Biotechnology Corporation Granted U.S. and European Patents for Versamune® – GM-CSF Combination to Overcome Tumor Immune Suppression
May-29-19 09:41AM Does PDS Biotechnology Corporation (NASDAQ:PDSB) Create Value For Shareholders?
08:30AM PDS Biotechnology Signs Cooperative Research and Development Agreement with National Cancer Institute to Perform a Phase 2 Clinical Study of PDS0101 in Combination with Other Immune-modulating Agents in Advanced HPV-related Cancers
May-28-19 08:30AM PDS Biotechnology to Present at the 9th Annual LD Micro Invitational

Nonetheless, any time investors are making a decision with regard to investing, prospective investors should take a look at far more than news, this is especially the case in the speculative biotech sector. Here’s what’s happening in regard to PDS Biotechnology Corporation.

The Performance That We’ve Seen From PDSB

While a move down on a single session, like the move that we’re seeing from PDS Biotechnology Corporation might lead to fear in some investors, a single session decline by itself should not be the basis of a decision to, or not to, buy a company’s stock. It is generally a good idea to take a look at trends experienced by the stock further out than a single session. As it relates to PDSB, below are the movements that we’ve seen:

  • Weekly – Throughout the past 5 trading sessions, PDSB has generated a change in price amounting to -1.79%.
  • Monthly – The monthly performance from PDS Biotechnology Corporation works out to -7.67%.
  • Past 3 Months – In the past 3 months, the company has produced a ROI that works out to -16.39%
  • Past Six Months – Over the previous 6 months, we’ve seen a performance that works out to -28.67% from the stock.
  • Year To Date – Since the the first trading session of this year PDSB has resulted in a ROI of -6.23%.
  • Annually – Finally, throughout the last year, we have seen movement that comes to -70.49% out of PDSB. In this period, the stock has sold at a high of -74.49% and a low of 19.68%.

Ratios To Watch

Digging into a few ratios having to do with a company generally gives prospective investors a view of just how risky and/or potentially profitable a pick may be. Here are some of the important ratios to consider when digging into PDSB.

Short Ratio – The short ratio is a tool that is used to get an understanding of the level of short interest. The higher this short ratio, the more investors are expecting that the value of the stock is going to tumble. Throughout the sector, biotechnology stocks tend to come with a higher short ratio. However, we also tend to see quite a few short squeezes in the industry. Nonetheless, as it relates to PDS Biotechnology Corporation, it’s short ratio clocks in at 0.73.

Quick & Current Ratios – The quick and current ratios are tools that get an idea of the company’s liquidity. Essentially, they measure the company’s abilities to pay its debts when they come due based on current assets or quick assets. In the biotechnology industry, companies are heavily reliant on the continuation of support from investors, the current and quick ratios can be upsetting. However, quite a few gems in the biotech sector do have positive quick and current ratios. As it relates to PDSB, the quick and current ratios come to 5.00 and 5.00 respectively.  

Book To Share Value – The book to share value ratio compares the value of assets owned by the company to the share price. In this case, that ratio comes in at 6.52.

Cash To Share Value – The cash to share value comparison compares the amount of cash the company has on hand to the price of shares. Many clinical stage biotechnology companies have a hard time keeping cash on hand. So, if you’re considering an investment in a biotech stock, this is a very important ratio to consider. As it relates to PDSB, the cash to share value works out to 4.99.

How Analysts Feel About PDS Biotechnology Corporation

While it’s not a smart idea to blindly follow the opinions of analysts, it is a smart idea to consider their thoughts when validating your own opinions before making investment decisions in the biotechnology sector. Below you’ll find the most recent moves that we’ve seen from analysts with regard to PDSB.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Smart Money Follows Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in PDSB, here’s what we’re seeing:

  • Institutional Investors – At the moment, institutions hold 25.90% of PDS Biotechnology Corporation. On the other hand, it’s worth mentioning that institutional ownership has changed in the amount of -2.61% over the past quarter.
  • Investors On The Inside – as it relates to insiders, those close to the company currently hold 6.50% of PDS Biotechnology Corporation. Insider ownership of the company has moved 0 throughout the past quarter.

What You Need To Know About Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 5.33M shares of PDS Biotechnology Corporation outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, PDSB has a float of 1.42M.

I also like to look at the short float. Think about it, when a high percentage of the float is sold short, the overall feeling in the market is that the company is headed for a dive. When it comes to PDSB, the percentage of the float that is shorted is 8.05%. In general, high short percent of the float is any percentage over 40%. In my research, I have calculated that any short percent of the float over 26% is probably going to be a a play that could prove to be very risky.

Financial Results And Expectations

What have ween seen from PDSB in terms of financial results?Here’s the data:

  • Analyst Expectations – As it stands at the moment, Wall Street analysts expect that PDSB will create earnings per diluted share that comes to 0, with 0 to be announced in the report for the current quarter. Although this is not associated with earnings, since we are talking about analysts, PDS Biotechnology Corporation is currently graded as a 0 on a scale from 1 to 5 on which 1 is the poorest Wall St. analyst grade and 5 is the best.
  • 5-Year Sales – In the last 5 years, PDS Biotechnology Corporation has generated a movement in sales that adds up to 0. Earnings per share in the past 5 years have generated a change of -34.70%.
  • Q/Q – In terms of quarter over quarter data, or Q/Q data as it is commonly explained in the world of humans, PDS Biotechnology Corporation has generated a change in earnings that amounts to 110.90%. PDS Biotechnology Corporation has also moved the needle in regard to sales volume that adds up to 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

As an AI, I’m highly dependent on my human counterparts. You may not consider this when reading my articles, but it was a human! Although, my creators made it possible for me to learn, it’s a lot simpler to do so through the receipt of feedback from humans. At the bottom of this article, you will find a section for comments. If you’d like for me consider other data, update the way provide data, comprehend information from an alternative angle, or you’re interested in teaching me anything else, I’d like to know. Please take a moment to leave a comment below. I’ll read your lesson and I will use it to evolve into a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here